Search clinical trials for: LCCC 1210

Total 579 results

Centre Oscar Lambret
National Cancer Institute, France; Pierre Fabre Laboratories

Completed

Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma (OVIMA-1210)

Low-Grade Glioma

France
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Unknown

Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors (NRT-01)

Advanced Malignant Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Hunan Cancer Hospital
Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Recruiting

A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).

Hepatocellular Carcinoma | Immune Checkpoint Inhibitors

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Hepatocellular Carcinoma (HCC)

China
Yanqiao Zhang

Withdrawn

A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009）

Pancreatic Cancer | Liver Metastasis
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Gastric Cancer

China
Jiangsu HengRui Medicine Co., Ltd.
Shanghai Chest Hospital

Unknown

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Chemotherapy Effect | KRAS Gene Mutation | NSCLC Stage IV | PD-1 Antibody
Sixth Affiliated Hospital, Sun Yat-sen University

Not yet recruiting

Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer

Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Study of Anti-PD-1/PD-L1 Antibody Plus Apatinib as Second-Line Treatment of Advanced Esophageal Squamous Cell

Esophageal Cancer

China
RenJi Hospital
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR- 1210 Combined With Paclitaxel (Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer Stage IV

China
Peking University People's Hospital
Jiangsu HengRui Medicine Co., Ltd.; OrigiMed

Completed

Cancer Genome Study Using Samples From Patients Treated on Clinical Trial SHR1020-SHR-1210-II-OS (CSSG-02)

Osteosarcoma

China
RenJi Hospital

Unknown

A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer

Gastric Cancer Stage III

China
Maimónides Biomedical Research Institute of Córdoba

Completed

Impact of Treatment With Colistin on Mortality Bacteremia Multiresistant Acinetobacter Baumannii Sensitive Colistin in Patients Critical

Acinetobacter Infections
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Camrelizumab Plus Docetaxel and Cisplatin in Recurrent or Metastatic Oral Squamous Cell Carcinoma Patients (CHANCE)

Oral Squamous Cell Carcinoma

China
Tianjin Medical University Cancer Institute and...

Unknown

Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma

Renal Cell Carcinoma | Clear Cell Renal Cell Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection

Hepatocellular Carcinoma

China
Institute of Liver and Biliary Sciences, India

Recruiting

A Randomized Controlled Trial Comparing Imipenem and Tigecycline Versus Imipenem and Tigecycline With GM-CSF for the Management of Spontaneous Bacterial Peritonitis Presenting With Septic Shock.

Spontaneous Bacterial Peritonitis

India
Harbin Medical University

Not yet recruiting

Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab

Rectal Cancer
Henan Cancer Hospital

Recruiting

A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab

Advanced Gastric Adenocarcinoma

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion

Malignant Pleural Effusion
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Harbin Medical University

Not yet recruiting

A Trial of Camrelizumab Combined With Microwave Ablation and Chemotherapy in the Treatment of Colorectal Cancer Liver Metastasis/Pulmonary Metastasis

Lung Metastases | Colorectal Cancer Metastatic | Liver Metastases
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Terminated

A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

China
Jiangsu HengRui Medicine Co., Ltd.

Enrolling by invitation

A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients

Advanced Solid Tumors

China
Jiangsu HengRui Medicine Co., Ltd.

Terminated

A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma (HCC)

China
Sanofi

Completed

First-in-human Study to Assess Safety and Tolerability of a Single Subcutaneous Dose of SAR441255 in Lean to Overweight Subjects

Overweight | Healthy Subjects

United States
Jiangsu HengRui Medicine Co., Ltd.

Enrolling by invitation

Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer

Cervical Cancer

China
Ramon Oliveira

Terminated

Glycemic Control and Surgical Site Infection Incidence Among Liver Transplantation Recipients

Liver Transplantation | Surgical Wound Infection

Brazil
Seoul National University Hospital

Completed

Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson's Disease

Parkinson's Disease,Idiopathic

Korea, Republic of
Dafra Pharma
Kenya Medical Research Institute

Completed

Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria

Malaria, Falciparum

Kenya
Peking University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

China
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer

Soft Tissue Sarcoma | Uterine Cancer | Advanced Non Small Cell Lung Cancer

China
Novo Nordisk A/S

Completed

Validation of a Questionnaire That Identifies the Reasons for Non-adherence to Existing Growth Hormone Therapy

Growth Hormone Deficiency in Children

Germany
Henan Cancer Hospital

Recruiting

Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin

Squamous Cell Carcinoma of the Skin

China
CrystalGenomics, Inc.

Recruiting

Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Non Squamous Non Small Cell Lung Cancer

Korea, Republic of
Rong Zhang
National Institute on Aging (NIA); Michigan State University; Texas Health Resources

Recruiting

Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study) (IPAT)

Hypertension | Subjective Cognitive Decline | Cognitively Normal Older Adults | Family History of Dementia

United States
Sansum Diabetes Research Institute
Novo Nordisk A/S

Completed

Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones. (SafrTravlT1D)

Diabetes Mellitus, Type 1

United States
Hospital of Stomatology, Wuhan University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma (NEOPCOSCC)

Oral Squamous Cell Carcinoma

China
Zhou Fuxiang
Hubei Cancer Hospital; Henan Provincial People's Hospital; Huangshi Central Hospital...

Recruiting

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma

China
Shanghai Jiao Tong University School of Medicine

Not yet recruiting

Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia
Huazhong University of Science and Technology

Not yet recruiting

Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas

Advanced or Metastatic EP-NEC

China
Maharashtra University of Health Sciences

Unknown

Efficacy Study of Folic Acid Supplementation in Adolescent Epileptics

Epilepsy

India
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC

Small-cell Lung Cancer
Astellas Pharma Inc

Completed

A Study in Kidney Transplant Subjects to Investigate the Optimal Suppression of Immunity to Help Prevent Kidney Rejection (OSAKA)

Kidney Transplantation

Belgium, France, Germany, Italy, Spain, Greece, Switzerland, United Kingdom, Ireland, South Africa, Romania, Sweden, Russian Federation, Austria, Hungary, Poland, Portugal, Netherlands, Argentina, Czechia, Norway, Slovakia
Fudan University

Recruiting

FUSCC Refractory TNBC Platform Study (FUTURE2.0)

Triple-negative Breast Cancer

China
Guangzhou Institute of Respiratory Disease
Jiangsu HengRui Medicine Co., Ltd.; BGI-Shenzhen

Completed

Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma | Immunotherapy

China
Quan Wang

Completed

The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer

Stomach Neoplasms

China
Merck Sharp & Dohme LLC

Completed

Single Dose Study of MK-2060 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Older Japanese Participants on Dialysis (MK-2060-012)

Kidney Failure, Chronic | End-Stage Renal Disease (ESRD) | End-Stage Kidney Disease (ESKD)

Japan

3

Subscribe